<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>爵士制药（Jazz Pharmaceuticals plc，股票代码：JAZZ）宣布了第三阶段 HERIZON-GEA-01 试验的积极疗效和安全性结果，该试验评估了 Ziihera 与化疗联合使用（无论是否与 PD-1 抑制剂 Tevimbra 联合使用）作为 HER2 阳性局部晚期或转移性胃食管腺癌成年患者的一线治疗，包括胃癌、胃食管交界癌和食管癌。</p>
<p>研究发现，两个实验组，即 Ziihera 加 tislelizumab 和化疗，以及 Ziihera 加化疗，均导致无进展生存期的统计学显著延长，疾病进展或死亡风险减少约 35%，与 trastuzumab 加化疗相比具有临床意义。</p>
<p>欲获取更多健康新闻，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

爵士制药

<p>爵士制药（Jazz Pharmaceuticals plc，股票代码：JAZZ）报告了 HERIZON-GEA-01 三期临床试验的积极结果，该试验评估了 Ziihera 与化疗联合使用（可选配 PD-1 抑制剂 Tevimbra）在治疗 HER2 阳性局部晚期或转移性胃食管腺癌成人患者中的效果。研究显示，进展无生存期显著延长，与曲妥珠单抗加化疗相比，疾病进展或死亡风险降低了 35%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as first-line treatment for adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction and esophagus.</p>
<div class="lb-trans"><p>爵士制药（Jazz Pharmaceuticals plc，股票代码：JAZZ）宣布了第三阶段 HERIZON-GEA-01 试验的积极疗效和安全性结果，该试验评估了 Ziihera 与化疗联合使用（无论是否与 PD-1 抑制剂 Tevimbra 联合使用）作为 HER2 阳性局部晚期或转移性胃食管腺癌成年患者的一线治疗，包括胃癌、胃食管交界癌和食管癌。</p>
</div><p>The study found both investigational arms, Ziihera plus tislelizumab and chemotherapy, and Ziihera plus chemotherapy, led to a statistically significant and clinically meaningful prolongation of progression-free survival with approximately 35% reduction in the risk of disease progression or death versus trastuzumab plus chemotherapy.</p>
<div class="lb-trans"><p>研究发现，两个实验组，即 Ziihera 加 tislelizumab 和化疗，以及 Ziihera 加化疗，均导致无进展生存期的统计学显著延长，疾病进展或死亡风险减少约 35%，与 trastuzumab 加化疗相比具有临床意义。</p>
</div><p>For More Such Health News, visit rttnews.com.</p>
<div class="lb-trans"><p>欲获取更多健康新闻，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

爵士制药公布了第三阶段 HERIZON-GEA-01 试验的积极结果